Jeffrey Landau
Corporate Officer/Principal bij CYTOMX THERAPEUTICS, INC.
Vermogen: 256 673 $ op 31-03-2024
Profiel
Jeffrey Landau is currently the Chief Business Officer, Senior VP & Head-Strategy at CytomX Therapeutics, Inc. He previously worked as the Vice President-Business Development at Catalyst Biosciences, Inc. from 2016 to 2021.
Prior to that, he was the Director-Corporate Development & Marketing at Threshold Pharmaceuticals, Inc. Mr. Landau has an undergraduate degree from Virginia Polytechnic Institute & State University and an MBA from Stanford Graduate School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 19-03-2024 | 117 740 ( 0.17% ) | 256 673 $ | 31-03-2024 |
Actieve functies van Jeffrey Landau
| Bedrijven | Functie | Begin |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Corporate Officer/Principal | 01-04-2021 |
Eerdere bekende functies van Jeffrey Landau
| Bedrijven | Functie | Einde |
|---|---|---|
| CATALYST BIOSCIENCES | Corporate Officer/Principal | 01-03-2021 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Sales & Marketing | - |
Opleiding van Jeffrey Landau
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
